Yahoo · Oct 28, 2026
What Would Slower New Drug Sales Do To Vertex Stock?
For questions about this article or underlying research, email [email protected].
ED
NASDAQ · EDIT
Editas Medicine, Inc.
Healthcare · Biotechnology
$2.93
Down-$0.02 (-0.68%)
Updated Oct 30, 2026, 12:11 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 217.72M
- P/E ratio
- -0.91
- Dividend yield
- 0.00%
- 52-week range
- $1.98 – $3.94
- Volume
- 3.23M
- Avg. volume
- 2.47M
Price performance · EDIT
EDIT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
EDIT closed at $2.93 after 21 trading sessions, up 16.27% for the selected period.
- Last close
- $2.93
- Period change
- +16.27%
- Period low
- $2.27
- Period high
- $2.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $2.945 | $2.98 | $2.86 | $2.93 | 3.23M |
| Oct 28, 2026 | $2.59 | $2.96 | $2.54 | $2.95 | 4.43M |
| Oct 27, 2026 | $2.41 | $2.61 | $2.37 | $2.60 | 3.08M |
| Oct 26, 2026 | $2.39 | $2.445 | $2.36 | $2.40 | 1.35M |
| Oct 23, 2026 | $2.44 | $2.45 | $2.30 | $2.40 | 1.31M |
| Oct 22, 2026 | $2.47 | $2.58 | $2.45 | $2.49 | 1.07M |
| Oct 21, 2026 | $2.59 | $2.60 | $2.50 | $2.51 | 1.14M |
| Oct 20, 2026 | $2.40 | $2.665 | $2.35 | $2.58 | 2.27M |
| Oct 19, 2026 | $2.38 | $2.43 | $2.27 | $2.42 | 2.01M |
| Oct 16, 2026 | $2.44 | $2.47 | $2.33 | $2.35 | 1.55M |
| Oct 15, 2026 | $2.26 | $2.465 | $2.25 | $2.44 | 1.86M |
| Oct 14, 2026 | $2.44 | $2.475 | $2.245 | $2.27 | 2.83M |
| Oct 13, 2026 | $2.73 | $2.73 | $2.44 | $2.445 | 2.45M |
| Oct 12, 2026 | $2.90 | $2.91 | $2.73 | $2.75 | 1.3M |
| Oct 9, 2026 | $2.85 | $2.97 | $2.71 | $2.90 | 3.09M |
| Oct 8, 2026 | $2.79 | $2.945 | $2.69 | $2.84 | 6.07M |
| Oct 7, 2026 | $2.71 | $2.845 | $2.659 | $2.75 | 2.26M |
| Oct 6, 2026 | $2.85 | $2.895 | $2.715 | $2.73 | 2.97M |
| Oct 5, 2026 | $2.62 | $2.81 | $2.555 | $2.79 | 3.02M |
| Oct 2, 2026 | $2.57 | $2.63 | $2.51 | $2.62 | 2.16M |
| Oct 1, 2026 | $2.61 | $2.62 | $2.52 | $2.52 | 1.54M |
Latest EDIT news
The latest Smart Investors Daily articles mentioning EDIT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EDIT research
Overview
Company profile and research snapshot.
Company profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.85
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Wells Fargo | Overweight | — |
| Sep 23, 2026 | Guggenheim | Buy | — |
| Aug 18, 2026 | Ladenburg Thalmann | Buy | — |
| May 5, 2026 | Chardan Capital | Buy | — |
| Mar 10, 2026 | Jones Trading | Buy | — |
News briefing
Generated Oct 30, 2026, 11:11 AM
Why Is EDIT Down Today?
Editas Medicine (EDIT) declined 0.68% today amid broader concerns about gene-editing therapy commercialization timelines and competitive pressures in the biotech sector. The stock's modest downturn reflects investor caution about the pace of new drug sales in the gene therapy space, particularly as peers like Vertex face similar headwinds.
Bottom line: Editas Medicine's modest decline reflects sector-wide concerns about gene therapy commercialization timelines rather than company-specific news. Investors should monitor upcoming clinical data and regulatory developments while remaining aware that broader market skepticism about new drug sales trajectories could continue to weigh on biotech valuations in the near term.
Yahoo · Oct 23, 2026
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 21, 2026
Why Should You Think About Vertex Differently Now?
Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time
Yahoo · Oct 14, 2026
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. European Society of Gene and Cell Therapy (ESGCT) CongressTitle: Novel targeted LNP delivery achieved in vivo CAR-T cell generation re
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
